Sequential neoadjuvant chemoradiotherapy (CRT) followed by curative surgery vs. primary surgery alone for resectable, non-metastasized pancreatic adenocarcinoma: NEOPA - a randomized multicenter phase III study (NCT01900327, DRKS00003893, ISRCTN82191749) by Tachezy, Michael et al.
Tachezy et al. BMC Cancer 2014, 14:411
http://www.biomedcentral.com/1471-2407/14/411STUDY PROTOCOL Open AccessSequential neoadjuvant chemoradiotherapy (CRT)
followed by curative surgery vs. primary surgery
alone for resectable, non-metastasized pancreatic
adenocarcinoma: NEOPA- a randomized
multicenter phase III study (NCT01900327,
DRKS00003893, ISRCTN82191749)
Michael Tachezy1†, Florian Gebauer1†, Cordula Petersen2, Dirk Arnold5, Martin Trepel3, Karl Wegscheider4,
Phillipe Schafhausen3, Maximilian Bockhorn1, Jakob Robert Izbicki1* and Emre Yekebas1,6Abstract
Background: Median OS after surgery in curative intent for non-metastasized pancreas cancer ranges under study
conditions from 17.9 months to 23.6 months. Tumor recurrence occurs locally, at distant sites (liver, peritoneum,
lungs), or both. Observational and autopsy series report local recurrence rates of up to 87% even after potentially
“curative” R0 resection. To achieve better local control, neoadjuvant CRT has been suggested for preoperative
tumour downsizing, to elevate the likelihood of curative, margin-negative R0 resection and to increase the OS rate.
However, controlled, randomized trials addressing the impact of neoadjuvant CRT survival do not exist.
Methods/Design: The underlying hypothesis of this randomized, two-armed, open-label, multicenter, phase III trial
is that neoadjuvant CRT increases the three-year overall survival by 12% compared to patients undergoing upfront
surgery for resectable pancreatic cancer. A rigorous, standardized technique of histopathologically handling Whipple
specimens will be applied at all participating centers. Overall, 410 patients (n = 205 in each study arm) will be enrolled
in the trial, taking into regard an expected drop out rate of 7% and allocated either to receive neoadjuvant CRT prior to
surgery or to undergo surgery alone. Circumferential resection margin status, i.e. R0 and R1 rates, respectively, surgical
resectability rate, local and distant disease-free and global survival, and first site of tumor recurrence constitute further
essential endpoints of the trial.
Discussion: For the first time, the NEOPA study investigates the impact of neoadjuvant CRT on survival of resectable
pancreas head cancer in a prospectively randomized manner. The results of the study have the potential to change
substantially the treatment regimen of pancreas cancer.
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Due to anatomical reasons, surgery for pancreatic cancer
frequently fails to achieve tumor-free resection margins
as the most important prerequisite for prevention from
tumor recurrence. This results in insufficient local control
that represents, beside early metastatic dissemination,
the reason for the catastrophic overall prognosis of the
disease. In the GITSG, EORTC, and ESPAC-1 trials,
local tumor recurrence was identified the first site
of failure in 39%, 53%, and 62% of enrolled patients,
respectively [1-3]. Even higher local recurrence rates of
up to 87% after “curative” surgery have been reported in
observational and autopsy series [4,5]. Recent studies
showing that the assessment of R1 status increases
substantially to 65%-85% when applying rigorous, fully
standardized techniques of handling Whipple specimens
[6-8] provide strong evidence that this high incidence
of local relapse is due to a tremendous rate of unre-
cognized, non-curative resections with microscopic
involvement of the circumferential resection margin
(R1 status). Therefore, the major impetus of neoad-
juvant CRT for pancreatic cancer is to increase the rate of
curative margin-negative R0 resections, hereby resulting
in improved survival.Figure 1 Trial flow. Patients are allocated either to intervention or control g
sequential neoadjuvant CRT (yellow bars) followed by curative surgery. Patien
of the study, subset analysis is performed stratifying patients with resectable v
chemotherapy. No postoperative, adjuvant EBRT in patients undergoing upfroMethods/Design
The presented study design is an open labeled random-
ized controlled phase III trial designed and organized
by the Department of General, Visceral and Thoracic
Surgery at the University Hospital Hamburg-Eppendorf,
approved by the Ethical Review Board of the Medical Asso-
ciation of Hamburg (Ethik-Kommission der Ärztekammer
Hamburg) and funded by the Federal Ministry of Education
and Research of the Federal Republic of Germany
(Bundesministerium für Bildung und Forschung der
Bundesrepublik Deutschland).
Patients fulfilling eligibility criteria are randomized to
either receive neoadjuvant radiochemotherapy followed
by surgical resection and facultative adjuvant therapy or
receive upfront surgery and adjuvant therapy (Figure 1).
Inclusion/exlusion criteria
Key inclusion criterion is the biopsy-proven, non-
metastasized, adenocarcinoma of the pancreatic head/
uncinate process larger than two centimeter in size (≥cT2)
and/or in close contact with the mesenterico-portal
axis and superior mesenteric artery (SMA) (less than
3 mm). Further inclusion and exclusion criteria are
presented in Table 1.roup after randomization. Patients in the intervention group undergo
ts in the control group are subjected to upfront surgery. After completion
s. borderline resectable lesions. Both groups will receive adjuvant
nt surgery (group 2) is performed.
Table 1 Inclusion and exclusion criteria
Key inclusion criteria Key exclusion criteria
• Histology-proven, resectable adenocarcinoma of the pancreatic head/
uncinate process with a tumor size greater 2 cm (≥cT2) and/or close
contact to the superior mesenteric vessels (≤3 mm in preoperative
staging).
• Age≤ 18 years
• Recurrent disease
• HInfiltration of extrapancreatic organs (except duodenum and
transverse colon)
• HNo evidence of metastasis to distant organs (liver, peritoneum, lung,
others).
• Persistent cholestasis/cholangitis despite adequate biliary stenting
• Serum creatinine level≤ 3.0 mg/dl • HGastric outlet obstruction, especially in the event of endoscopically
evidenced tumor invasion into the gastroduodenal mucosa.
• HSerum total bilirubin level≤ 3.0 mg/dl in the absence of biliary obstruction
(In the event of biliary obstruction, patients allocated to the CRT group must
undergo interventional endoscopy or percutaneous drainage for biliary
decompression. Post-interventionally, bilirubin levels should be≤ 3.0 mg/dl
before patients are subjected to CRT. In control patients undergoing upfront
surgery, serum total bilirubin levels≤ 10.0 mg/dl are tolerated, unless clinical
and laboratory signs of severe cholangitis take place. Patients with serum
total bilirubin level > 10.0 mg/dl undergo preoperative biliary decompression,
preferentially by interventional endoscopy)
• Tumor specific pre-treatment
• History of gastrointestinal perforation, e.g. perforated colonic diverticulitis,
abdominal abscess or intestinal fistula within 6 months prior to potential
study participation
• Radiographic evidence of severe portal hypertension/cavernomatous
transformation that may, at the discretion of the participating
investigators, hamper surgery
• Other concurrent malignancies except for basal cell cancer of the skin
and in-situ cervical cancer, Premalignant hematologic disorders, e.g.
myelodysplastic syndrome
• White blood cell count≥ 3.5 × 109/ml, platelet count≥ 100 × 109/ml • Severe organ dysfunctions (e.g. Liver cirrhosis ≥ Child B; Cardio-pulmonal
diseases (NYHA≥ III, arrhythmia Lown III/IV, global respiratory insufficiency);
Ascites; Acute pancreatitis; bleeding diathesis, coagulopathy, need for
full-dose anticoagulation or INR > 1.5; other severe diseases that might
prevent completion of the treatment regimen)
• HAbility to understand and willingness to consent to formal
requirements for study participation
Written informed consent
• Chronic infectious diseases, especially immune deficiency syndromes,
e.g. HIV infection, active tuberculosis within 12 months prior to potential
study participation
• History of severe neurologic disorders, e.g. cerebrovascular ischemia
• History of prior deep venous thrombosis or pulmonary embolism
• Pregnant or nursing women are ineligible and patients of reproductive
potential must agree to use an effective contraceptive method during
participation in this trial and for 6 months following the trial
• Serious medical, psychological, familial, sociological or geographical
conditions or circumstances potentially hampering compliance with the
study protocol and follow-up
Participation in other clinical trials during the last 6 months before
allocation to trial
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Baseline diagnostic staging consists of abdominal multi-
detector computed tomography (MDCT) according to a
standardized protocol. For determination of resectability,
MDCT with at least 16 rows applying both oral and intra-
venous contrast media is performed. MDCT-based imaging
focuses on the upper abdomen with native, arterial, and
parenchyma phase, where the parenchyma phase should
include the pelvis. Imaging criteria derived from the recent
consensus definition of the Society of Surgical Oncology, the
American Society of Clinical Oncology and the American
Hepato-Pancreatico-Biliary Association [9] are applied
for preoperative assessment of local resectability.
 Potential Resectability: visualizable fat plane around
celiac and superior mesenteric arteries, and patent
superior mesenteric/portal vein (SMV/PV). Borderline Resectability: substantial superior
mesenteric/portal vein impingement, tumor
abutment on the SMA < 180°, GDA encasement up
to the origin of the hepatic artery, or colonic/
mesenteric root invasion (Prior to treatment
initiation, patients will be coded as resectable or
borderline resectable.)
Randomization-based allocation to one of both treat-
ment arms is performed independently from this stratifi-
cation. However, subgroup analysis regarding the potential
benefits of neoadjuvant CRT will be performed after
completion of the trial.
Radiographic workup is completed by chest X-ray.
Baseline laboratory and operative eligibility tests (includ-
ing CA19-9 and CEA assessment) will be performed for
every patient in routine preoperative work-up.
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study inclusion. Therefore, in the event of a suspicious
mass in the pancreatic head without evidence of dis-
tant metastasis, the eligibility of patients is assessed by
endosonography-guided fine-needle aspiration (EUS-FNA).
Explorative laparoscopy/laparotomy may alternatively
be performed when EUS-guided biopsy is technically
not feasible, e.g. due to previous gastric surgery with
diversion of the gastroduodenal continuity, or when
histologic findings are inconclusive.
Patients are considered eligible and checked for fulfil-
ment of inclusion and exclusion criteria. Patients, who
meet inclusion criteria, are asked for study participation
after appraisal of all findings in a multidisciplinary tumor
board. Randomization is performed after patients have
signed written informed consent.
Radiochemotherapy
Patients allocated to undergo neoadjuvant CRT will
receive Gemcitabine 300 mg/m2/weekly for 6 weeks
combined with 3-D-conformal external beam radio-
therapy (EBRT) according to the following protocol:
Clinical Target Volume (CTV) is defined based on
standardized, preoperative MDCT imaging with frontal
and sagittal reconstruction of CT scans. For better
differentiation of the small bowel, celiac trunk vessels,
superior mesenteric artery, mesenterico-portal axis,
and neighboring organs, oral contrast ingestion and
intravenous contrast enhancement is performed. Con-
ventionally fractionated irradiation with a total dose of
50.4 Gy is delivered over 28 days in 1.8 Gy fractions
targeting also frequently involved, peripancreatic “at risk”
lymph nodes (Group 8, 10, 11, 13, 14, 16, 17) including an
additional safety margin of 1.5 cm. EBRT is performed
from Monday to Friday resulting in a total treatment time
of 38 days if protocol starts on Monday. Dose limits for
organs at risk are ≤ 30 Gy to 50% of the liver volume, ≤
20 Gy to 50% of the right kidney volume, ≤ 20 Gy to 30%
of the left kidney volume, and ≤ 45 Gy to the spinal cord.
Depending on the clinical condition, surgery is sched-
uled within a time frame of 3 (earliest) to 6 weeks (latest)
after completion of neoadjuvant CRT.
Surgery
Patients allocated to the reference group undergo primary
surgery in curative intent. Both study arms undergo,
depending on the individual tumor site, either pylorus-
preserving pancreatoduodenectomy (PPPD) or classic
partial pancreatoduodenectomy (cPD) with standard lymph-
adenectomy (SLA). Intraoperative frozen-sections will be
routinely performed from the pancreatic transection surface
and the common bile duct (CBD). SLA includes lymph
node dissection at the anterior and posterior aspect of the
pancreatic head, the pylorus, the hepatoduodenal ligament,the right aspect of the SMA, and the hepatic artery in its
course at the superior part of the pancreatic head. For surgi-
cal quality control, post-resectional photo-documentation is
requested.
In cases of unexpected intraoperative unresectability
(distant metastasis, tumor invasion into the celiac trunk,
SMA, mesenteric root), patients undergo suitable bypass
procedures. This is followed by palliative CTx, e.g. Gemci-
tabine 1000 mg/m2 6 cycles at day 1, 8, 15 of each 28-day
cycle plus/minus Erlotinib.
Irrespective of whether or not neoadjuvant CRT has
been performed, all patients undergo adjuvant CTx,
preferentially with Gemcitabine 1000 mg/m2 6 cycles
at day 1, 8, 15 of each 28-day cycle.
Histopathological examination
To minimize inter-institutional bias in histopathologic
reporting, standardized handling of Whipple specimens
is essential. In line with recent developments, guidance
will be given regarding the extent and technique of
tissue sampling, and microscopic involvement will be
defined by a minimum clearance of 2 mm [10]. To
ensure accurate histopathology reporting including
margin status assessment, the participating study
centres will follow a standardized protocol with axial
slicing of the Whipple specimen and extensive tissue
sampling at all circumferential margins. Histopathology
results, especially regarding the R-status, may be re-
evaluated at the discretion of two experts in pancreatic
pathology in any participating center in a blinded fashion at
regular intervals [6,7]. This designated panel of histopathol-
ogists will ensure that (1) the agreed pathology protocol
meets the set standards in terms of accuracy and reprodu-
cibility and (2) that the protocol is uniformly applied in all
centers. The pathology protocol will in particular address
the specific diagnostic challenges that are posed by
tumour regression following pre-operative CRT.
Follow up
Study visits with alternating ultrasound and MDCT
investigations are performed in 3 month intervals for
18 months post-operatively, and in 6 month intervals
thereafter (Figure 2). Study visits include clinical exam-
ination (Karnofsky-index) and routine laboratory investi-
gations including tumor marker assessment (CEA, CA
19–9). Either MDCT or abdominal ultrasound imaging
is scheduled according to the following flow:
 MDCT imaging and chest X-ray at 6, 12, 18, 24, 30,
36 months after randomization. Additional MDCT
scanning may be performed in the event of suspected
tumor recurrence
 Abdominal ultrasound at 3, 9, and 15 months after
randomization.
Figure 2 Follow-up and study visits. Study visits will be performed in 3-months intervals within the first 18 months and in 6-months intervals
thereafter. Total follow-up will be 24 months after end-of-recruitment or 36–72 months after randomization.
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was intraoperatively not feasible or in whom follow-up
investigations evidences tumor recurrence at any site
(local, distant, both) will undergo follow-up study visits.
Any palliative therapy and supportive means will be docu-
mented and annotated in CRF sheets. In contrast to pa-
tients undergoing curative surgery, imaging investigations,
especially MDCT, will be conducted only for medical rea-
sons, i.e. routine follow-up MDCT will be omitted.
Study objective
Efficacy of neoadjuvant CRT in improving 3-year survival
probability from 30% in the control arm undergoing up-
front surgery without neoadjuvant CRT to 42% (relative
increase of 40%) in the study arm undergoing CRT. The
underlying guess of a 30% 3-year survival probability in
the control group derives from an assumed median overall
survival (MOS) of 20.7 months which corresponds with a
MOS of 17.9 months to 23.6 months reported in several
randomized trials.
Primary and secondary endpoints
Primary endpoint of the study is the survival time of the
patients, precisely the three year overall survival starting
from study inclusion/randomization. Key secondary end-
points are the following:
 Histology-proven R0 resection rate based on a
standardized histopathological handling of the
surgical specimen.
 Frequency of moderate and severe toxicity events
and drop-out rate due to therapy related toxicity
(NCI Common Toxicity Criteria v2.0)
 Resectability rate (Note: includes both R0 and R1
resection status). Rate of unexpected intraoperative irregularities,
operative time, blood transfusion requirement,
postoperative morbidity rate, especially that of
pancreatic fistula, and mortality rate
 Rate of patients with severe postoperative
complications (postop. recovery > 8 weeks)
rendering adjuvant treatment worthless
 Disease progression during neoadjuvant therapy
 Quality of life analysis (EORTC QLQ C30
questionnaire)
 Median disease-free survival (DFS, local and distant),
overall survival (OS)
 First site of tumor recurrence
Proposed sample size/power calculations
The sample size calculation is based on the assumption
that the 3-year survival probability in the control arm is
30% corresponding to a median overall survival (MOS) of
20.7 months, which is in line with MOS of 17.9 months to
23.6 months reported in clinical trials [3,11-13]. The
sample size calculation is based on both a scrutinized
literature research and own data sampled in a prospect-
ive pancreas cancer database (Department of General,
Visceral and Thoracic Surgeryat the University of Hamburg).
Overall, this database encompasses 1023 patients oper-
ated on for pancreatic cancer from 1/1993 to 12/2010,
whose survival data are available. Part of these data has
been published [14-16].
Reliable data from phase III trials regarding outcome
after sequential CRT followed by surgery for pancreas
cancer do not exist. Different neoadjuvant regimens,
the lack of clear inclusion criteria (pooling of poten-
tially resectable tumours with borderline resectable
and unresectable, locally advanced lesions), and dispar-
ities in the accuracy of histopathological evaluation
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vival [17]. Therefore, reported MOS in these series
ranging from 23.0 months to 34.0 months and 3-year
survival probability ranging from 0% to 48% have to be
interpreted with caution [18-28].
The trial is expected to be able to demonstrate an
absolute (relative) increase of 12% (40%) to 42% 3-year
survival with a power of 80%. For this purpose, a
group-sequential design with 4 stages spending a total
alpha of 5% is considered. A sample size calculation
was performed using ADDPLAN 5.0. According to this
calculation, 398 fully evaluable patients have to be
included.
Quality control
The procedures set out in this study protocol are de-
signed to ensure that the sponsor and the investigator
abide by the principles of the ICH Guideline for GCP
(E6) and the Declaration of Helsinki concerning the
conduct, evaluation and documentation of the study.
The study will also be performed adhering to the local
legal conditions and regulations and to the applicable
regulatory requirements.
To ensure comparability of tumor characteristics in
both treatment arms, allocation of patients is per-
formed by 1:1 randomization regarding both the entire
trial and the respective centres using a computerized
online randomization tool. Trial site effects are not
expected because all participating centres are known
to have a high case load in pancreatic surgery. The
study design does not enable to blind patients before
surgery. However, the trial statistician will check the
final analysis of the trial results for statistical correct-
ness based on an anonymized database.
A standardized histopathology protocol as a mandatory
prerequisite of the trial will be applied to minimize
inter-institutional disparities, in particular regarding
circumferential resection status (CRM; R0 vs. R1). To
avoid bias in the histopathological examination, the
respective pathologist is unaware of whether or not
CRT has been performed.
All withdrawals will be documented including the
reason. All data of patients who withdraw, e.g., who are
discontinued prematurely will be documented and dis-
cussed, as necessary, in the final report of the trial.
All available data will be included in the analyses and
will be summarized as far as possible. Every effort will
be undertaken to fulfill all protocol requirements
regarding the collection and management of data.
Missing data will be dealt with on an individual basis
and will be subject to data queries. Unless otherwise
specified, there will be no substitution of missing data.
Missing data will not be replaced but will be handled
as ‘missing’ in the statistical evaluation.An advisory Data and Safety Monitoring Board (DSMB)
evaluates the risk to the patients on the accrued data
provided by the sponsor and the monitor. The multi-
centre character of the study poses special challenges
as to quality control performed on an ad hoc or real-
time basis or quarterly, as appropriate. The DSMB will
especially focus on inter-institutional differences in
diagnostic work-up, clinical staging accuracy, surgery,
histopathology reporting, and non-surgical therapy. A
further major task of the DSMB is to check for poten-
tially elevated surgical morbidity in CRT patients (intra-
operative blood loss, anastomotic leakage rates, etc.).
Discussion
Randomized trials evidencing the superiority of sequen-
tial CRT and surgery strategies over surgery alone do
not exist. Nonetheless, in several centers predominantly
in the U.S. (in contrast to European centers), neoadju-
vant CRT followed by surgery has meanwhile become a
“standard” approach towards patients with resectable
pancreas cancer. Without clear evidence for the super-
iority of such an attitude compared to surgery alone,
different treatment schedules have been evaluated and
are actually under investigation (NCT00049348, NCT
00089024, NCT0042673, NCT00557492, NCT00456599).
The scientific rationale for neoadjuvant CRT derives
from 2 aspects: EBRT for local control and CTx for both,
sensitizing EBRT and early treatment of occult distant
metastasis. It is more likely to be completed in its full
course (80%-90%) when administered preoperatively,
whereas between 21% and 35% of patients may not
complete adjuvant treatment due to inadequate postop-
erative recovery or even never receive such a treatment
due to severe postoperative morbidity [29]. Recovery
from surgery may especially be delayed when pancreatic
fistula constituting the most frequent surgical complica-
tion after PD arises. A potential “benefit” of preoperative
CRT is in this context that the prevalence of pancreatic
fistula formation after PD is, as a result of fibrotic alter-
ations of the gland, lower after preoperative radiation
[25,30]. The comparison of the rate of patients with
severe surgical morbidity precluding adjuvant CTx,
which is planned in both treatment arms, is therefore a
secondary endpoint of this trial.
Consistently, most trials on pancreatic cancer report
that R0 status is, as compared to R1 patients, not an
independent, beneficial prognostic factor. Based on re-
cent studies clearly evidencing that histopathology tends
to understage potential involvement of circumferential
resection margins if specimens are processed by non-
standardized techniques, there is growing awareness that
most relevant studies on curatively resected pancreas
cancer are significantly biased by substantial weaknesses
in the histopathological staging of Whipple specimens.
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patients, who are underreported and would be staged
“R1” when applying standardized pathological handling
procedures [6]. Application of a standardized histo-
pathologic protocol known to increase staging accuracy
[6,8,31] is a crucial methodological part of this application.
Based on these considerations, the potential impact of
CRT on circumferential margin status represents a sub-
stantial secondary endpoint of this application.
In examining published and ongoing series addressing
the benefit of neoadjuvant CRT for resectable pancreatic
cancer on a whole, it is important to state that no
consensus exists regarding radiation and CT regimens.
This reflects both the wide range of applied agents (5-FU,
Cisplatin, Gemcitabine, Mitomycin C, Bevacizumab,
Capecitabine, Docetaxel, Oxaliplatin) and investigated
radiation doses (30 Gy to 50.4 Gy) with fairly wide
treatment fields including prophylactic regional nodal
radiation.
Chemomodulation with 5-FU has shown to increase
survival in irradiated unresectable, locally advanced pan-
creatic cancer (LAPC) [32]. In the neoadjuvant setting, the
majority of trials evaluated 5-FU- or Gemcitabine-based
CRT, combined with or without Cisplatin [23,27,33-37].
Current results of neoadjuvant Gemcitabine-based CRT
in borderline resectable LAPC show good tolerability,
and a meaningful overall survival of 31 to 34 months was
reported for patients receiving resection after induction
treatment [23,27]. Furthermore, Gemcitabine-based CRT
was feasible and well tolerated in the postoperative setting,
also in comparison to adjuvant Gemcitabine alone
[37]. In the recent trials by Wilkowski and colleagues,
further escalation of Gemcitabine based CRT by Cisplatin
(compared to 5-FU based CRT) in unresectable LAPC
showed significantly higher grade 3–4 RTOG toxicity
without improvement of survival rates [33]. Whereas in
the adjuvant or palliative setting CRT is mainly up to 50
Gy, reported preoperative protocols range from 30 to
50.4 Gy in 1.8-3 Gy fractions combined with Gemcita-
bine 100–1000 mg/m2 weekly [23,24,26,27,34,37-44].
With respect to these data, a CRT schedule with weekly
doses of Gemcitabine 300 mg/m2 and 50.4 Gy in 1.8 Gy
fractions was selected.
After curative resection, the CONKO-001 trial showed
that Gemcitabine significantly improved disease free
survival (DFS) compared to observation alone [13]. Similar
results were obtained in a Japanese phase III trial, showing
significant increased DFS and a trend towards better
overall survival [45]. The RTOG 97–04 compared sys-
temic 5-FU to Gemcitabine for 3 weeks before and
12 weeks after CRT with 5-FU revealing a trend towards
better survival in the Gemcitabine arm [46]. Although
the ESPAC-3 trial did not identify any survival benefit
of Gemcitabine compared to 5-FU, Gemcitabine showedbetter tolerability and lower incidence of sever adverse
events [11]. Therefore, Gemcitabine is regarded as the
current standard for adjuvant treatment and will be
administered in both treatment arms for adjuvant
therapy [47].
Despite the questionable radiosensitivity and chemo-
sensitivity of the disease, there are 2 strong arguments in
favour of neoadjuvant CRT. The first is that negative
microscopic resection margin status (R0) as the predom-
inant prerequisite for long-term, local control is in the
majority of patients (>50%) not achieved by surgery
alone. Advocates of CRT argue that this “limitation” of
any surgical therapy is addressed by the radiation “com-
ponent”, although the impact of potentially increased
curative R0 rates on outcome is still largely unknown.
Secondly, it appears to be conclusive to administer pre-
operatively systemic CTx for occult distant metastases
non visualizable by current diagnostic imaging tools
[21,23,48,49]. Despite of these considerations, scientific
evidence that neoadjuvant CRT followed by surgery
beneficially impacts survival compared to surgery alone
has not been provided. Case series report median OS
following neoadjuvant therapy from 10 to 36 months
[27,50,51]. The fact that despite the lack of controlled,
randomized studies, many institutions, especially in the
U.S., subject pancreas cancer patients to neoadjuvant
CRT underlies the fundamental need for this trial.Competing interests
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